Related references
Note: Only part of the references are listed.Dapagliflozin add-on to metformin in type 2 diabetes inadequately controlled with metformin: a randomized, double-blind, placebo-controlled 102-week trial
Clifford J. Bailey et al.
BMC MEDICINE (2013)
Long-Term Efficacy of Dapagliflozin in Patients With Type 2 Diabetes Mellitus Receiving High Doses of Insulin A Randomized Trial
John P. H. Wilding et al.
ANNALS OF INTERNAL MEDICINE (2012)
Evaluation of vulvovaginal symptoms and Candida colonization in women with type 2 diabetes mellitus treated with canagliflozin, a sodium glucose co-transporter 2 inhibitor
Paul Nyirjesy et al.
CURRENT MEDICAL RESEARCH AND OPINION (2012)
Dose-Ranging Effects of Canagliflozin, a Sodium-Glucose Cotransporter Inhibitor, as Add-On to Meiformin in Subjects With Type 2 Diabetes
Julio Rosenstock et al.
DIABETES CARE (2012)
Effects of Dapagliflozin, an SGLT2 Inhibitor, on HbA1c, Body Weight, and Hypoglycemia Risk in Patients With Type 2 Diabetes Inadequately Controlled on Pioglitazone Monotherapy
Julio Rosenstock et al.
DIABETES CARE (2012)
Effects of Dapagliflozin on Body Weight, Total Fat Mass, and Regional Adipose Tissue Distribution in Patients with Type 2 Diabetes Mellitus with Inadequate Glycemic Control on Metformin
Jan Bolinder et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2012)
Dapagliflozin Versus Glipizide as Add-on Therapy in Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control With Metformin A randomized, 52-week, double-blind, active-controlled noninferiority trial
Michael A. Nauck et al.
DIABETES CARE (2011)
Pharmacokinetics and pharmacodynamics of dapagliflozin, a novel selective inhibitor of sodium-glucose co-transporter type 2, in Japanese subjects without and with type 2 diabetes mellitus
S. Kasichayanula et al.
DIABETES OBESITY & METABOLISM (2011)
Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with glimepiride: a randomized, 24-week, double-blind, placebo-controlled trial
K. Strojek et al.
DIABETES OBESITY & METABOLISM (2011)
Long-Term Effects of Intensive Glucose Lowering on Cardiovascular Outcomes
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Dapagliflozin Monotherapy in Type 2 Diabetic Patients With Inadequate Glycemic Control by Diet and Exercise A randomized, double-blind, placebo-controlled, phase 3 trial
Ele Ferrannini et al.
DIABETES CARE (2010)
In Vitro Characterization and Pharmacokinetics of Dapagliflozin (BMS-512148), a Potent Sodium-Glucose Cotransporter Type II Inhibitor, in Animals and Humans
M. Obermeier et al.
DRUG METABOLISM AND DISPOSITION (2010)
Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomised, double-blind, placebo-controlled trial
Clifford J. Bailey et al.
LANCET (2010)
Survival as a function of HbA1c in people with type 2 diabetes: a retrospective cohort study
Craig J. Currie et al.
LANCET (2010)
Intensive glycemic control and cardiovascular disease: an update
Aparna Brown et al.
NATURE REVIEWS CARDIOLOGY (2010)
Comorbidity Affects the Relationship Between Glycemic Control and Cardiovascular Outcomes in Diabetes A Cohort Study
Sheldon Greenfield et al.
ANNALS OF INTERNAL MEDICINE (2009)
Dapagliflozin, a Novel SGLT2 Inhibitor, Induces Dose-Dependent Glucosuria in Healthy Subjects
B. Komoroski et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2009)
Dapagliflozin, a Novel, Selective SGLT2 Inhibitor, Improved Glycemic Control Over 2 Weeks in Patients With Type 2 Diabetes Mellitus
B. Komoroski et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2009)
From the Triumvirate to the Ominous Octet: A New Paradigm for the Treatment of Type 2 Diabetes Mellitus
Ralph A. DeFronzo
DIABETES (2009)
Sodium-Glucose Cotransport Inhibition With Dapagliflozin in Type 2 Diabetes
James F. List et al.
DIABETES CARE (2009)
Intensive Glycemic Control and the Prevention of Cardiovascular Events: Implications of the ACCORD, ADVANCE, and VA Diabetes Trials A position statement of the American Diabetes Association and a scientific statement of the American College of Cardiology Foundation and the American Heart Association
Jay S. Skyler et al.
DIABETES CARE (2009)
A Study of Dapagliflozin in Patients With Type 2 Diabetes Receiving High Doses of Insulin Plus Insulin Sensitizers Applicability of a novel insulin-independent treatment
John P. H. Wilding et al.
DIABETES CARE (2009)
The Impact of Weight Gain on Motivation, Compliance, and Metabolic Control in Patients with Type 2 Diabetes Mellitus
F. Xavier Pi-Sunyer
POSTGRADUATE MEDICINE (2009)
Improving efficiency of inferences in randomized clinical trials using auxiliary covariates
Min Zhang et al.
BIOMETRICS (2008)
Dapagliflozin, a selective SGLT2 inhibitor, improves glucose homeostasis in normal and diabetic rats
Songping Han et al.
DIABETES (2008)
Glycaemic control among patients with type 2 diabetes mellitus in seven European countries: findings from the Real-Life Effectiveness and Care Patterns of Diabetes Management (RECAP-DM) study
F. Alvarez Guisasola et al.
DIABETES OBESITY & METABOLISM (2008)
Discovery of dapagliflozin: A potent, selective renal sodium-dependent glucose cotransporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes
Wei Meng et al.
JOURNAL OF MEDICINAL CHEMISTRY (2008)
10-year follow-up of intensive glucose control in type 2 diabetes
Rury R. Holman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Is glycemic control improving in US adults?
Thomas J. Hoerger et al.
DIABETES CARE (2008)
Insulin-associated weight gain in diabetes - causes, effects and coping strategies
David Russell-Jones et al.
DIABETES OBESITY & METABOLISM (2007)
Initial monotherapy with either metformin or sulphonylureas often fails to achieve or maintain current glycaemic goals in patients with Type 2 diabetes in UK primary care
M. N. Cook et al.
DIABETIC MEDICINE (2007)
Active sugar transport in health and disease
E. M. Wright et al.
JOURNAL OF INTERNAL MEDICINE (2007)
Glucose transporters in human renal proximal tubular cells isolated from the urine of patients with non-insulin-dependent diabetes
H Rahmoune et al.
DIABETES (2005)